Glomerular Filtration Rate
"Glomerular Filtration Rate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance.
| Descriptor ID |
D005919
|
| MeSH Number(s) |
E01.370.390.400.300 G08.852.357
|
| Concept/Terms |
Glomerular Filtration Rate- Glomerular Filtration Rate
- Filtration Rate, Glomerular
- Filtration Rates, Glomerular
- Glomerular Filtration Rates
- Rate, Glomerular Filtration
- Rates, Glomerular Filtration
|
Below are MeSH descriptors whose meaning is more general than "Glomerular Filtration Rate".
Below are MeSH descriptors whose meaning is more specific than "Glomerular Filtration Rate".
This graph shows the total number of publications written about "Glomerular Filtration Rate" by people in this website by year, and whether "Glomerular Filtration Rate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 3 | 5 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 5 | 6 |
| 2007 | 2 | 4 | 6 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 4 | 4 |
| 2010 | 2 | 5 | 7 |
| 2011 | 2 | 16 | 18 |
| 2012 | 3 | 9 | 12 |
| 2013 | 2 | 4 | 6 |
| 2014 | 3 | 7 | 10 |
| 2015 | 4 | 11 | 15 |
| 2016 | 6 | 9 | 15 |
| 2017 | 4 | 14 | 18 |
| 2018 | 4 | 14 | 18 |
| 2019 | 4 | 11 | 15 |
| 2020 | 2 | 9 | 11 |
| 2021 | 1 | 4 | 5 |
| 2022 | 1 | 7 | 8 |
| 2023 | 0 | 1 | 1 |
| 2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glomerular Filtration Rate" by people in Profiles.
-
Modeling Metformin and Dapagliflozin Pharmacokinetics in Chronic Kidney Disease. AAPS J. 2024 Aug 19; 26(5):94.
-
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. Adv Ther. 2024 Jun; 41(6):2500-2518.
-
Rilparencel (Renal Autologous Cell Therapy-REACT®) for Chronic Kidney Disease and Type 1 and Type 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Redosing Triggers. Am J Nephrol. 2024; 55(3):389-398.
-
Patterns of cortical oxygenation may predict the response to stenting in subjects with renal artery stenosis: A radiomics-based model. J Cardiovasc Magn Reson. 2024; 26(1):100993.
-
ALTERATIONS IN HISTIDINE METABOLISM IS A FEATURE OF EARLY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD). Trans Am Clin Climatol Assoc. 2024; 134:47-65.
-
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med. 2023 12; 176(12):1606-1616.
-
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression. J Am Soc Nephrol. 2023 12 01; 34(12):2025-2038.
-
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials. Kidney Int. 2023 07; 104(1):181-188.
-
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis. Clin J Am Soc Nephrol. 2023 05 01; 18(5):602-612.
-
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023 02 13; 38(2):372-383.